Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Modern developments in molecular genetics have led oncologists not only to define tumors according to their anatomical site, stage, and histological type, but also to appreciate the heterogeneity between tumors according to their specific molecular, genetic, or immunological subtype, empowering oncologists to, ideally, provide more individually tailored treatment to particular patients and their specific tumor subtype by using highly targeted therapies. In this chapter, circulating biomarkers and pharmacodynamics markers for target inhibition, among other markers, will be discussed and exemplified with regard to major oncological entities.

Original publication





Book title

Principles of Translational Science in Medicine: From Bench to Bedside, Third Edition

Publication Date



195 - 202